Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat
Identifieur interne : 004544 ( Main/Exploration ); précédent : 004543; suivant : 004545Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat
Auteurs : Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 6‐OHDA‐lesioned rat, Animal, Animals, Antagonist, Antiparkinson Agents (pharmacology), Antiparkinson agent, Behavior, Animal (drug effects), Chemotherapy, Corpus Striatum (metabolism), Corpus striatum, Dopamine (metabolism), Dose-Response Relationship, Drug, Excitatory Amino Acid Antagonists (pharmacology), Ifenprodil, Intracerebral administration, Levodopa (pharmacology), Localization, Male, Microinjections, NMDA receptor, NMDA receptor antagonists, Oxidopamine, Parkinson Disease (metabolism), Parkinson Disease (psychology), Parkinson Disease, Secondary (chemically induced), Parkinson disease, Parkinson's disease, Parkinsonism, Pathogenesis, Piperidines (pharmacology), Pyrrolidinones (pharmacology), Rat, Rats, Rats, Sprague-Dawley, Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors), Receptors, N-Methyl-D-Aspartate (metabolism), Treatment, basal ganglia, globus pallidus, striatum.
- MESH :
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , metabolism : Dopamine, Receptors, N-Methyl-D-Aspartate.
- chemical , pharmacology : Antiparkinson Agents, Excitatory Amino Acid Antagonists, Levodopa, Piperidines, Pyrrolidinones.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal.
- metabolism : Corpus Striatum, Parkinson Disease.
- psychology : Parkinson Disease.
- Animals, Dose-Response Relationship, Drug, Male, Microinjections, Oxidopamine, Rats, Rats, Sprague-Dawley.
Abstract
Treatments for Parkinson's disease based on replacement of lost dopamine have several problems. Following loss of dopamine, enhanced N‐methyl‐D‐aspartate (NMDA) receptor‐mediated transmission in the striatum is thought to be part of the cascade of events leading to the generation of parkinsonian symptoms. We determined the localisation and pharmacological characteristics of NMDA receptors that play a role in generating parkinsonian symptoms within the striatum. Rats were lesioned unilaterally with 6‐hydroxydopamine (6‐OHDA), and cannulae implanted bilaterally to allow injection of a range of NMDA receptor antagonists at different striatal sites. When injected rostrally into the dopamine‐depleted striatum, the glycine site partial agonist, (+)‐HA‐966 (44–400 nmol) caused a dose‐dependent contraversive rotational response consistent with an antiparkinsonian action. (+)‐HA‐966 (400 nmol) had no effect when infused into more caudal regions of the dopamine‐depleted striatum, or following injection into any striatal region on the dopamine‐intact side. To determine the pharmacological profile of NMDA receptors involved in inducing parkinsonism in 6‐OHDA‐lesioned rats, a range of NMDA receptor antagonists was infused directly into the rostral striatum. Ifenprodil (100 nmol) and 7‐chlorokynurenate (37 nmol), but not MK‐801 (15 nmol) or D‐APV (25 nmol) elicited a dramatic rotational response when injected into the dopamine‐depleted striatum. This pharmacological profile is not consistent with an effect mediated via blocking NR2B‐containing NMDA receptors. The effect of intrastriatal injection of ifenprodil was increased in animals previously treated with levodopa (L‐dopa) methyl ester. This was seen as an increase in on‐time and in peak rotational response. We propose that stimulation of NR2B‐containing NMDA receptors in the rostral striatum underlies the generation of parkinsonian symptoms. These studies are in line with previous findings suggesting that administration of NR2B‐selective NMDA receptor antagonists may be therapeutically beneficial for parkinsonian patients, when given de novo and following L‐dopa treatment. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10107
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000006
- to stream Istex, to step Curation: 000006
- to stream Istex, to step Checkpoint: 002E36
- to stream PubMed, to step Corpus: 003A67
- to stream PubMed, to step Curation: 003A67
- to stream PubMed, to step Checkpoint: 003B67
- to stream Ncbi, to step Merge: 000784
- to stream Ncbi, to step Curation: 000784
- to stream Ncbi, to step Checkpoint: 000784
- to stream Main, to step Merge: 006550
- to stream PascalFrancis, to step Corpus: 002719
- to stream PascalFrancis, to step Curation: 000602
- to stream PascalFrancis, to step Checkpoint: 002834
- to stream Main, to step Merge: 006873
- to stream Main, to step Curation: 004544
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat</title>
<author><name sortKey="Nash, Joanne E" sort="Nash, Joanne E" uniqKey="Nash J" first="Joanne E." last="Nash">Joanne E. Nash</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:62361BA501CDDD7FA8BF244FFD50A0509E7D82B2</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10107</idno>
<idno type="url">https://api.istex.fr/document/62361BA501CDDD7FA8BF244FFD50A0509E7D82B2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000006</idno>
<idno type="wicri:Area/Istex/Curation">000006</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E36</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Nash J:characterisation:of:striatal</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12112191</idno>
<idno type="wicri:Area/PubMed/Corpus">003A67</idno>
<idno type="wicri:Area/PubMed/Curation">003A67</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B67</idno>
<idno type="wicri:Area/Ncbi/Merge">000784</idno>
<idno type="wicri:Area/Ncbi/Curation">000784</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000784</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Nash J:characterisation:of:striatal</idno>
<idno type="wicri:Area/Main/Merge">006550</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0370370</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002719</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000602</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002834</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Nash J:characterisation:of:striatal</idno>
<idno type="wicri:Area/Main/Merge">006873</idno>
<idno type="wicri:Area/Main/Curation">004544</idno>
<idno type="wicri:Area/Main/Exploration">004544</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat</title>
<author><name sortKey="Nash, Joanne E" sort="Nash, Joanne E" uniqKey="Nash J" first="Joanne E." last="Nash">Joanne E. Nash</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="455">455</biblScope>
<biblScope unit="page" to="466">466</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">62361BA501CDDD7FA8BF244FFD50A0509E7D82B2</idno>
<idno type="DOI">10.1002/mds.10107</idno>
<idno type="ArticleID">MDS10107</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐OHDA‐lesioned rat</term>
<term>Animal</term>
<term>Animals</term>
<term>Antagonist</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson agent</term>
<term>Behavior, Animal (drug effects)</term>
<term>Chemotherapy</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus striatum</term>
<term>Dopamine (metabolism)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Ifenprodil</term>
<term>Intracerebral administration</term>
<term>Levodopa (pharmacology)</term>
<term>Localization</term>
<term>Male</term>
<term>Microinjections</term>
<term>NMDA receptor</term>
<term>NMDA receptor antagonists</term>
<term>Oxidopamine</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Parkinsonism</term>
<term>Pathogenesis</term>
<term>Piperidines (pharmacology)</term>
<term>Pyrrolidinones (pharmacology)</term>
<term>Rat</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term>
<term>Receptors, N-Methyl-D-Aspartate (metabolism)</term>
<term>Treatment</term>
<term>basal ganglia</term>
<term>globus pallidus</term>
<term>striatum</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Piperidines</term>
<term>Pyrrolidinones</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Male</term>
<term>Microinjections</term>
<term>Oxidopamine</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animal</term>
<term>Antagoniste</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Corps strié</term>
<term>Ifenprodil</term>
<term>Localisation</term>
<term>Parkinson maladie</term>
<term>Parkinsonisme</term>
<term>Pathogénie</term>
<term>Rat</term>
<term>Récepteur NMDA</term>
<term>Traitement</term>
<term>Voie intracérébrale</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Treatments for Parkinson's disease based on replacement of lost dopamine have several problems. Following loss of dopamine, enhanced N‐methyl‐D‐aspartate (NMDA) receptor‐mediated transmission in the striatum is thought to be part of the cascade of events leading to the generation of parkinsonian symptoms. We determined the localisation and pharmacological characteristics of NMDA receptors that play a role in generating parkinsonian symptoms within the striatum. Rats were lesioned unilaterally with 6‐hydroxydopamine (6‐OHDA), and cannulae implanted bilaterally to allow injection of a range of NMDA receptor antagonists at different striatal sites. When injected rostrally into the dopamine‐depleted striatum, the glycine site partial agonist, (+)‐HA‐966 (44–400 nmol) caused a dose‐dependent contraversive rotational response consistent with an antiparkinsonian action. (+)‐HA‐966 (400 nmol) had no effect when infused into more caudal regions of the dopamine‐depleted striatum, or following injection into any striatal region on the dopamine‐intact side. To determine the pharmacological profile of NMDA receptors involved in inducing parkinsonism in 6‐OHDA‐lesioned rats, a range of NMDA receptor antagonists was infused directly into the rostral striatum. Ifenprodil (100 nmol) and 7‐chlorokynurenate (37 nmol), but not MK‐801 (15 nmol) or D‐APV (25 nmol) elicited a dramatic rotational response when injected into the dopamine‐depleted striatum. This pharmacological profile is not consistent with an effect mediated via blocking NR2B‐containing NMDA receptors. The effect of intrastriatal injection of ifenprodil was increased in animals previously treated with levodopa (L‐dopa) methyl ester. This was seen as an increase in on‐time and in peak rotational response. We propose that stimulation of NR2B‐containing NMDA receptors in the rostral striatum underlies the generation of parkinsonian symptoms. These studies are in line with previous findings suggesting that administration of NR2B‐selective NMDA receptor antagonists may be therapeutically beneficial for parkinsonian patients, when given de novo and following L‐dopa treatment. © 2002 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Nash, Joanne E" sort="Nash, Joanne E" uniqKey="Nash J" first="Joanne E." last="Nash">Joanne E. Nash</name>
</region>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004544 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004544 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:62361BA501CDDD7FA8BF244FFD50A0509E7D82B2 |texte= Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat }}
This area was generated with Dilib version V0.6.23. |